Therapeutic mRNA delivery to leukocytes

Yasmin Granot-Matok; Edo Kon; Niels Dammes; Gilad Mechtinger; Dan Peer

doi:10.1016/j.jconrel.2019.05.032

Therapeutic mRNA delivery to leukocytes

Yasmin Granot-Matok, Edo Kon, Niels Dammes, Gilad Mechtinger, Dan Peer

Tel Aviv University

Research output: Contribution to journal › Review article › peer-review

Abstract

In the past few years mRNA molecules have become an attractive class of new drugs with numerous opportunities. mRNA therapeutics holds great potential for the treatment of a variety of diseases and is an emerging field both in academia and in the pharma industry. Among the various mRNA-based therapeutic approaches, immunotherapy is one of the pioneering and most advanced therapy to date. Immune cells manipulation using mRNA is commonly used for vaccination purposes, but its potential is much broader. In this review, we discuss the promise of mRNA delivery to leukocytes. We aim to provide an overview of the main progress in this field, as well as the challenges in expanding the scope of mRNA therapy for different therapeutic applications. We also discuss the main technological developments for overcoming mRNA therapy limitations, including mRNA rational design and delivery platforms.

Original language	English
Pages (from-to)	165-175
Number of pages	11
Journal	Journal of Controlled Release
Volume	305
DOIs	https://doi.org/10.1016/j.jconrel.2019.05.032
State	Published - 10 Jul 2019

All Science Journal Classification (ASJC) codes

Pharmaceutical Science

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jconrel.2019.05.032

Cite this

@article{2042fe03bfb44255b87b1965c09677ee,

title = "Therapeutic mRNA delivery to leukocytes",

abstract = "In the past few years mRNA molecules have become an attractive class of new drugs with numerous opportunities. mRNA therapeutics holds great potential for the treatment of a variety of diseases and is an emerging field both in academia and in the pharma industry. Among the various mRNA-based therapeutic approaches, immunotherapy is one of the pioneering and most advanced therapy to date. Immune cells manipulation using mRNA is commonly used for vaccination purposes, but its potential is much broader. In this review, we discuss the promise of mRNA delivery to leukocytes. We aim to provide an overview of the main progress in this field, as well as the challenges in expanding the scope of mRNA therapy for different therapeutic applications. We also discuss the main technological developments for overcoming mRNA therapy limitations, including mRNA rational design and delivery platforms.",

author = "Yasmin Granot-Matok and Edo Kon and Niels Dammes and Gilad Mechtinger and Dan Peer",

note = "Publisher Copyright: {\textcopyright} 2019 Elsevier B.V.",

year = "2019",

month = jul,

day = "10",

doi = "10.1016/j.jconrel.2019.05.032",

language = "الإنجليزيّة",

volume = "305",

pages = "165--175",

journal = "Journal of Controlled Release",

issn = "0168-3659",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Therapeutic mRNA delivery to leukocytes

AU - Granot-Matok, Yasmin

AU - Kon, Edo

AU - Dammes, Niels

AU - Mechtinger, Gilad

AU - Peer, Dan

PY - 2019/7/10

Y1 - 2019/7/10

N2 - In the past few years mRNA molecules have become an attractive class of new drugs with numerous opportunities. mRNA therapeutics holds great potential for the treatment of a variety of diseases and is an emerging field both in academia and in the pharma industry. Among the various mRNA-based therapeutic approaches, immunotherapy is one of the pioneering and most advanced therapy to date. Immune cells manipulation using mRNA is commonly used for vaccination purposes, but its potential is much broader. In this review, we discuss the promise of mRNA delivery to leukocytes. We aim to provide an overview of the main progress in this field, as well as the challenges in expanding the scope of mRNA therapy for different therapeutic applications. We also discuss the main technological developments for overcoming mRNA therapy limitations, including mRNA rational design and delivery platforms.

AB - In the past few years mRNA molecules have become an attractive class of new drugs with numerous opportunities. mRNA therapeutics holds great potential for the treatment of a variety of diseases and is an emerging field both in academia and in the pharma industry. Among the various mRNA-based therapeutic approaches, immunotherapy is one of the pioneering and most advanced therapy to date. Immune cells manipulation using mRNA is commonly used for vaccination purposes, but its potential is much broader. In this review, we discuss the promise of mRNA delivery to leukocytes. We aim to provide an overview of the main progress in this field, as well as the challenges in expanding the scope of mRNA therapy for different therapeutic applications. We also discuss the main technological developments for overcoming mRNA therapy limitations, including mRNA rational design and delivery platforms.

UR - http://www.scopus.com/inward/record.url?scp=85066268885&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2019.05.032

DO - 10.1016/j.jconrel.2019.05.032

M3 - مقالة مرجعية

SN - 0168-3659

VL - 305

SP - 165

EP - 175

JO - Journal of Controlled Release

JF - Journal of Controlled Release

ER -

Therapeutic mRNA delivery to leukocytes

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this